Vistagen Therapeutics, Inc. (VTGN)
Develops nasal spray treatments for anxiety, depression, and other brain disorders.
$0.23+0.01%Healthcare
StockGlow Score
Bearish
BearishBullish
1 year ago-92.0%
The outlook
VTGN is trading near its 52-week low, well below both its 50- and 200-day moving averages. Analyst sentiment is mixed, with an average price target suggesting significant upside from current levels, though coverage appears limited. The overall backdrop remains bearish based on recent price action and trend positioning.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range1% of the way from its 52-week low to high
Price targetAvg target +330% vs current price
Market cap
$9.6M
52-wk high
$5.14
52-wk low
$0.20
50-day avg
$0.48
200-day avg
$1.46
Trailing P/E
—